Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

SELLAS Life Sciences Group

NASDAQ SLS
$1.36 0.07 4.80%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 13 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

43.53M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
41.34M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.71
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
32.12M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
27.83 %

Upcoming events SELLAS Life Sciences Group

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart SELLAS Life Sciences Group

Stock analysis SELLAS Life Sciences Group

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-1.17 21.82
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
-5.46 5.25
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-1.46 9.04
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.08 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
465.85 5.86

Price change SELLAS Life Sciences Group per year

2.33$ 15.08$
Min Max

Summary analysis SELLAS Life Sciences Group

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure SELLAS Life Sciences Group

Revenue and net income SELLAS Life Sciences Group

All parameters

Stock news SELLAS Life Sciences Group

All news
10 October 2023 в 23:41

Sellas Life Sciences Group Gets FDA Orphan Drug Designation to Treat Type of Leukemia

10 October 2023 в 23:36

Sellas Life Sciences Group Gets FDA Orphan Drug Designation to Treat Type of Leukemia

24 February 2023 в 01:50

SELLAS Life Sciences Group Shares Drop 34% After Hours On Proposed Public Offering

24 February 2023 в 01:50

SELLAS Life Sciences Group Shares Drop 34% After Hours On Proposed Public Offering

14 November 2022 в 21:31

SELLAS Life Sciences Group Shares Drop 40% on Clinical Trial Update

14 November 2022 в 21:26

SELLAS Life Sciences Group Shares Drop 40% on Clinical Trial Update

About company SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.
Address:
Times Square Tower, New York, NY, United States, 10036
Company name: SELLAS Life Sciences Group
Issuer ticker: SLS
ISIN: US81642T2096
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2017-12-29
Sector: Healthcare
Industry: Biotechnology
Site: https://www.sellaslifesciences.com

On which stock exchange are SELLAS Life Sciences Group (SLS) stocks traded?

SELLAS Life Sciences Group (SLS) stocks are traded on NASDAQ.

What is the ticker of SELLAS Life Sciences Group stocks (SLS)?

The stock ticker of SELLAS Life Sciences Group’s stocks or in other words, the code is SLS. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does SELLAS Life Sciences Group (SLS) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, SELLAS Life Sciences Group (SLS) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are SELLAS Life Sciences Group (SLS) stocks traded?

SELLAS Life Sciences Group (SLS) stocks are traded on the NASDAQ exchange in dollars.

What is the price of SELLAS Life Sciences Group (SLS) stocks today?

The current price of SELLAS Life Sciences Group stocks on 12.05.2024 is 1.355 dollars. per share.

What is the dynamics of SELLAS Life Sciences Group (SLS) stocks from the beginning of the year?

SELLAS Life Sciences Group (SLS) quotes have increased by 50.56% from the beginning of the year up to 1.355 dollars. per 1 stocks.

How much did SELLAS Life Sciences Group (SLS) stocks increase in мае 2024?

This month SELLAS Life Sciences Group (SLS) quotes have increased by 5.86% to 1.355 dollars. per share.

How much are SELLAS Life Sciences Group (SLS) stocks worth?

Today, on October, 12.05.2024 SELLAS Life Sciences Group’s (SLS) stocks cost 1.355 dollars..

What is the market capitalization of SELLAS Life Sciences Group (SLS)?

Capitalization is the market value of SELLAS Life Sciences Group (SLS) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 12.05.2024, the market capitalization of SELLAS Life Sciences Group (SLS) is estimated at about 43528708 dollars.